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Abstract
Background: Epithelial-mesenchymal transition (EMT) is a crucial process in tumorigenesis since tumor cells attain
fibroblast-like features enabling them to invade to surrounding tissue. Two transcription factors, TWIST and SNAI1,
are fundamental in regulating EMT.
Methods: Immunohistochemistry was used to study the expression of TWIST and SNAI1 in 109 pharyngeal
squamous cell carcinomas.
Results: Tumors with intense stromal staining of TWIST relapsed more frequently (p = 0.04). Tumors with both
positive TWIST and SNAI1 immunoreactivity in the stroma were at least Stage II (p = 0.05) and located more often in
hypopharynx (p = 0.035). Tumors with negative immunostaining of TWIST and SNAI1 in the stromal compartment
were smaller (T1-2) (p = 0.008), less advanced (SI-II) (p = 0.031) and located more often in the oropharynx (p = 0.007).
Patients with negative SNAI1 and TWIST immunostaining in tumor stroma had a better 5-year disease-specific and
overall survival (p = 0.037 and p = 0.014 respectively).
Conclusion: TWIST and SNAI1 expression in stromal cells is associated with clinical and histopathological
characteristics that indicate progressive disease. Negative expression of these EMT-promoting transcription factors
predicts a better outcome.
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Background
Head and neck cancer, over 90% of which are squamous
cell carcinomas (SCC) [1], is the sixth most common
malignancy and eighth leading cause of cancer death
worldwide [2]. The prognosis of pharyngeal squamous
cell carcinoma (PSCC) is the poorest of all head and neck
cancers and the survival rate has not improved signifi-
cantly in the last two decades [3]. The delay in making a
diagnosis, the appearance of second primaries, as well as
regional and distant metastases all contributes to the
poor survival [2].
Carcinogenesis is a multistep process characterized by
the gradual accumulation of mutations in cancer cells.
However, cancer cells also modify their stromal sur-
roundings to create a supportive environment to permit
tumor progression.
The tumor stroma is the compartment providing the
connective-tissue framework of the tumor. This includes
fibroblasts, immune and inflammatory cells, fat cells and
blood-vessels. Normal fibroblasts are able to inhibit cancer
progression. But during early tumor development, how-
ever, there are changes in the local tissue microenviron-
ment which shifts to growth-promoting stage due to local
conditions such as chronic inflammation [4]. Moreover,
cancer associated fibroblasts have been shown to be
important promoters of tumor growth and progression
[5].
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process during which cellular phenotype and function
become changed towards a migrating and invasive form.
This process is crucial in embryogenesis. But, it is also fre-
quently seen in tumor progression [6]. It is triggered by a
diverse set of stimuli e.g. growth-factor signaling, hypoxia
and also by tumor-stromal cell interactions with transcrip-
tion factors such as SNAI1, TWIST, SLUG and ZEB1 [7].
One important property of TWIST and SNAI1 is the direct
repression of E-cadherin, resulting in a loss of cell-cell
adhesion [8,9]. TWIST and SNAI1 have also antiapoptotic
properties [10,11] they influence cell polarity [12], and
angiogenesis [13].
TWIST is a helix-loop-helix transcription factor, which
induces motility and metastatic phenotype in cell lines
[14,15]. High expression of TWIST is associated with
aggressive tumor properties and poor survival in oesopha-
geal and cervical SCC [16,17]. In our previous study, it
was found that the endothelial and stromal staining of
SNAI1 was associated with poor survival in PSCC [18]. In
a recent study of oral SCC a small group of cases with
abundant SNAI1 expression in tumor cell nuclei had sig-
nificantly shorter DSS [19]. In head and neck squamous
cell carcinoma (HNSCC), Yang et al have shown that co-
expression of TWIST and SNAI1 was associated with a
shorter metastasis-free period and reduced overall survival
[20]. The prognosis of cases with TWIST and SNAI1 co-
expression is also worse in hepatocellular carcinoma and
non-small cell lung cancer compared with cases where
only one of the transcriptional factors is expressed [15,21].
According to our hypothesis TWIST and SNAI1 could
affect survival in PSCC. Previous studies have focused
mainly on nuclear and cytoplasmic expression of
TWIST and SNAI1 in epithelial cancer cells, not on the
whole tumor microenvironment. Furthermore, there are
only a few studies into TWIST expression in HNSCC.
The aim of present study was to separately evaluate
stromal and epithelial cancer cell expression of TWIST
in PSCC cohort and its co-expression with SNAI1. We
also wanted to investigate the association of these tran-
scription factors with clinicopathological features and
their impact on patient survival over the long-term.
Methods
Patients
The original clinical data from hospital records included
all patients from eastern Finland diagnosed with oro- or
hypopharyngeal squamous cell carcinoma between years
1971 and 1997 (n = 138). Sufficient material for immuno-
histochemical analyses was available from 109 original
tumor samples and the representativeness of the groups
was confirmed by c
2-test [22]. The histological differentia-
tion was evaluated according to the World Health Organi-
zation (WHO) classification [23] and the tumor staging
was based on the Classification of the International Asso-
ciation Against Cancer (UICC) [24]. The Karnofsky per-
formance status at the time of diagnosis was scored [25].
The patients were monitored until death or April 2009
and none of the patients was lost to follow-up.
Tissue microarray and immunohistochemistry
The most representative areas of each tumor were chosen
by an experienced pathologist (YS) and marked for inclu-
sion into tissue microarrays that were constructed using
1.0 mm core Manual tissue arrayer I (Beecher Instru-
ments, Silver Spring, MD, USA). Four-μm-thick sections
were first deparaffinized and rehydrated in the routine
manner. Then the sections for TWIST analysis were
heated in a microwave oven (800 W) for 3 × 5 min in
citrate buffer (pH 6.0) and sections for SNAI1 analysis in
Tris-EDTA buffer (pH 9.0), incubated in that buffer for
18 min and washed twice for 5 min in phosphate buffered
saline (PBS). Endogenous peroxidase activity was blocked
with hydrogen peroxide (5%, 5 min) followed by washing
with water 2 × 5 min and with PBS for 2 × 5 min. Non-
specific binding was blocked with 1.5% normal serum in
PBS for 25 min at room temperature. The sections were
incubated over night at 4°C with a mouse monoclonal
antibody against TWIST (1:100 dilution) (Abcam,
Cambridge, UK) and a mouse monoclonal antibody
against SNAI1 (1:750 dilution) [26,27] respectively. In
the negative controls, the primary antibody was omitted.
The slides were then washed with PBS for 2 × 5 min and
incubated with a biotinylated secondary antibody (ABC
Vectastain Elite Kit, Vector Laboratories, Burlingame, CA,
USA) for 35 min at room temperature. Subsequently, the
slides were washed twice with PBS for 5 min, incubated
for 45 min in preformed avidin-biotinylated peroxidase
complex (ABC Vectastain Elite Kit, Vector Laboratories,
Burlingame, CA, USA) and washed with PBS for 2 ×
5 min. The color was developed with diaminobenzidine
tetrahydrochloride (DAP) (Sigma, St. Louis, MO, USA).
The samples were counterstained with Mayer’s haematox-
ylin, washed, dehydrated, cleared and mounted with
Depex (BDH, Poole, UK). Pharyngeal tumor tissue and
ovarian tumor tissue with known positive TWIST and
SNAI1 stainings were used as positive controls.
Evaluation of the expression pattern
Both TWIST and SNAI1 array spots were initially evalu-
ated separately by three observers (AJ-M, RS, YS and AJ-M,
HT, YS respectively) without any knowledge of the clinical
data. The results were compared and in case of a disagree-
ment, the case was re-evaluated by all investigators in order
to reach a consensus. In TWIST array spots the stromal
and epithelial cancer cell immunoreactivity was classified
into 5 categories according to the proportion of positive
cell nuclei as follows; 1 = 0-4%, 2 = 5-25%, 3 = 26-50%,
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noreactivity in stromal and epithelial cancer cells were
counted on a continuous scale. The tumors were divided to
TWIST and SNAI1 positive and negative cases according
to the median of the evaluations (1 in epithelial and 2 in
stromal cells for TWIST; 2 in epithelial and 3 in stromal
cells for SNAI1).
Statistical analyses
The chi-squared test was used in analyzing frequency
tables of two variables. Frequency tables with three vari-
ables were calculated with one-way ANOVA -test. A
Mann-Whitney test was used to examine the associations
between continuous variables. The association between
TWIST and SNAI1 staining was evaluated by Spearman
test. Univariate survival analyses were evaluated using the
Kaplan-Meier method. The statistical differences between
the curves were analyzed using the log-rank test. Multi-
variate survival analysis was calculated using Cox’sp r o p o r -
tional hazards model. Disease-specific survival was defined
as the time between the date of primary diagnostic biopsy
and the date of death due to pharyngeal cancer. SPSS 14.0
software (SPSS Inc., Chicago, IL, USA) was used for statis-
tical analyses.
Ethics
The research plan was approved by the ethical committee
of Kuopio University and Kuopio University Hospital and
permission for accessing data from the Finnish Cancer
Registry and from hospital records was obtained from by
the Finnish Ministry of Social Affairs and Health.
Results
Cohort
The patients and treatment characteristics are summarized
in Table 1. The mean age of the patients at the time of
diagnosis was 65 years with a male predominance. Almost
70% of the carcinomas were advanced stages (III-IV) and
76% had a moderate to poor degree of differentiation. The
most common primary treatment modality was radiother-
apy either alone or postoperatively.
Expression of TWIST
TWIST staining was detected in the cell nuclei of stro-
mal fibroblasts and epithelial cancer cells (Figure 1).
The stromal expression of TWIST was clearly more
common than its expression in the epithelial tumor
cell compartment. According to the median (> = 2), 44
of 109 tumors (40%) were classified as being stroma
positive. According to median (> = 1), 38 epithelial
compartments of the tumors out of 109 (35%) were
Table 1 Clinicopathological features of the patients with
pharyngeal squamous cell carcinoma (n = 109)
Variable n (%)
Mean age at the time of presentation, years 65 [40-89]*
Median duration of the symptoms, months 3 [0-76]*
Sex
Male 82 (75)
Female 27 (25)
Site of primary tumor
Oropharynx 69 (63)
Hypopharynx 40 (37)
T category
T1 13 (12)
T2 40 (37)
T3 21 (19)
T4 35 (32)
N category
N0 63 (58)
N1 16 (15)
N2 27 (25)
N3 3 (3)
M category
M0 105 (96)
M1 4 (4)
Stage
S I 9 (8)
S II 25 (23)
S III 21 (19)
S IV 54 (50)
Histologic differentiation
Well 26 (24)
Moderate 48 (44)
Poor 35 (32)
Karnofsky performance status score
≥ 70% 72 (66)
< 70% 37 (34)
Primary treatment
Radiotherapy 69 (63)
Surgery and radiotherapy 31 (28)
Surgery 5 (5)
No cancer specific treatment 4 (4)
Recurrence
No 37 (34)
Yes 41 (38)
No response 31 (28)
Second primary tumor
No 99 (91)
Yes 10 (9)
Median OS, months 20.9 [1.1-401.3]*
*Values in square brackets indicate range.
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immunostaining of TWIST in the cell nuclei of epithe-
lial and stromal cells is detailed in Table 2.
Clinicopathological variables and TWIST expression
Tumors with abundant TWIST expression in stromal
fibroblast cell nuclei (category 3 or more in both sam-
ples) relapsed more frequently (p = 0.04). Stromal stain-
ing was more common in hypopharyngeal than
oropharyngeal tumors (p = 0.015). Stromal nuclear
expression of TWIST did not associate with the
patient’s age, gender, tumor size, stage, histological
grade or smoking habits. However, there was a tendency
for an association between stromal TWIST immunor-
eactivity and larger tumor size (T3-4) and advanced
stage (SIII-IV) (p = 0.064 and p = 0.086 respectively). In
our cohort, epithelial cancer cell staining of TWIST did
not associate significantly with any of the clinicopatholo-
gical variables. However, patients with epithelial cancer
cell immunoreactivity tended to have a worse Karnofsky
Figure 1 Expression of TWIST and SNAI1 nuclear transcription factors in pharyngeal squamous cell carcinoma. Positive (A) and negative
(B) epithelial TWIST immunostaining in squamous epithelial cells (immunoscores 3/5 and 0/5, respectively). Positive stromal TWIST staining in
stromal spindled cells (C; immunoscore 4/5). Positive SNAI1 immunostaining in the spindled stromal cells (D; immunoscore > 30 cells). Tumors A
and D are moderately differentiated (grade 2/3) and tumours B and C poorly differentiated (grade 3/3). The stages are IV (A), II (B), IV (C) and IV
(D). (Original magnifications of x100 in low power views and × 400 in the inserts).
Table 2 Proportion of TWIST expression in cell nuclei of epithelial cancer cells and stromal fibroblasts
Category TWIST expression % Epithelial cancer cells
n (%)
Stromal cells
n (%)
1 0-4 78 (71) 28 (26)
2 5-25 19 (18) 41 (37)
3 26-50 4 (4) 24 (22)
4 51-75 7 (6) 14 (13)
5 ≥ 76 0 (0) 1 (1)
nd* nd 1 (1) 1 (1)
*nd = not defined.
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display neck lymph node metastases (p = 0.099).
TWIST and SNAI1 co-expression
SNAI1 expression has been described in detail in our
previous study with the same patient material [18].
Epithelial cancer cell immunoreactivity of the nuclei was
present in 75 (68%) with stromal immunoreactivity in
49 (46%) of the array spots (Figure 1). A strong associa-
tion between TWIST and SNAI1 expression in stromal
cell nuclei was detected (p = 0.001, Spearman’s correla-
tion coefficient 0.33). But no association was detected in
the epithelial cancer cell nuclei (p = 0.206, Spearman’s
correlation coefficient 0.10).
To evaluate tumors undergoing TWIST and SNAI1
related EMT we selected a group, where both TWIST
and SNAI1 were positive and renamed it EMT+ (n = 29,
27%). All these EMT+ tumors were at least Stage II (p =
0.05) and were located more often in hypopharynx (p =
0.035). TWIST and SNAI1 co-expression did not corre-
late with histological grade, metastases or smoking habits.
Correspondingly, tumors lacking both TWIST and
SNAI1 stromal immunoreactivity (n = 42, 38.5%) were
renamed EMT-. These tumors were smaller (T1-2) (p =
0.008), less advanced (SI-II) (p = 0.031) and located more
often in oropharynx (p = 0.007). Furthermore, non-smo-
kers had more EMT- tumors (p = 0.034). It was possible
to detect either SNAI1 or TWIST stromal immunoreac-
tivity in thirty eight (35%) patients. Tumors were larger
according to the number of positive transcription factors
(p = 0.034) (Table 3). It was estimated that tumors were
also more often located in hypopharynx when both tran-
scription factors were positive (p = 0.023) (Table 4).
Survival analyses
In Kaplan-Meier univariate analysis neither stromal nor
epithelial cancer cell expression of TWIST alone asso-
ciated with DSS or OS. Tumors with both TWIST and
SNAI1 negativity had a statistically significantly better 5-
year survival compared with patients who displayed posi-
tive TWIST and/or SNAI1 stromal cell nuclei staining
(DSS p = 0.037; OS p = 0.014) (Figure 2a). The 5-year
prognosis tended to worsen depending on the number of
positive transcription factors detected (DSS p = 0.113;
OS p = 0.043) (Figure 2b). In the Cox proportional
hazards model, tumor stage and Karnofsky performance
status score were the only independent prognostic factors
for survival (p < 0.001 in both).
Discussion
During EMT, epithelial cells attain mesenchymal and
promigratory features and are able to become detached
from the epithelial layer. EMT is also a crucial property
during morphogenesis. But, it has also a central role in
tumor progression. Different transcription factors such
as SNAI1 and TWIST regulate gene expression patterns
that underlie EMT [6]. In the present study, tumors that
did not express TWIST or SNAI1 in stroma were smal-
ler, of lower stage and were more often situated in the
oropharynx. Tumors with negative stromal immunos-
taining for TWIST and SNAI1 had a significantly better
5-year DSS. Interestingly, the patients with stromal
TWIST and SNAI1 negative tumors were more often
non-smokers. In bladder cancer TWIST expression has
also been shown to be influenced by smoking [28]. This
agrees with a previous hypothesis that smoking can
modulate the expression of EMT markers. Aromatic
hydrocarbon B[a]P in tobacco smoke has shown to
cause EMT-like, partly irreversible dynamic changes in
gene expression such as TWIST up-regulation [29].
In the present study, nuclear staining intensity of
TWIST was detected in the stromal component more
often than in epithelial cancer cells. The same phenom-
enon was recently observed with SNAI1 in oral SCC
[ 1 9 ] .T h e r ew a sa l s oat r e n dt om o r ep r o n o u n c e d
TWIST staining intensity in larger and advanced stage
tumors. Stromal expression of TWIST was more fre-
quent in hypopharyngeal than in oropharyngeal tumors.
It remains unclear whether this is due to more advanced
disease stage at the time of diagnosis or it represents a
true feature of the hypopharyngeal tumors with very
poor overall prognosis.
TWIST has several properties that facilitate tumor
progression including the triggering of EMT, inhibition
of apoptosis and the enhancement of angiogenesis
[9,13]. TWIST has shown to induce EMT through chro-
matin remodeling [30]. TWIST overexpression corre-
lates with E-cadherin downregulation in HNSCC cell
line [30]. However, in a recent study of nasopharyngeal
carcinoma SNAI1 expression associated with repressed
E-cadherin expression while TWIST expression had no
affect on expression of E-cadherin [31]. Thus, EMT
Table 3 Expression of TWIST and/or SNAI1 in tumor stroma in different T categories
Stromal expression of TWIST and/or SNAI1
T classification EMT-n (%) TWISTor SNAI1 + n (%) EMT+n (%) p
T1 and T2 27 (25) 15 (14) 11 (10) 0.034
T3 and T4 15 (14) 23 (21) 18 (16)
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ferent kinds of carcinomas.
To date, there is only one other study which has exam-
ined the association between Twist expression and clinico-
pathological features in HNSCC. In a rather small cohort
of various head and neck squamous cell carcinomas (n =
50), nuclear and cytoplasmic staining of TWIST correlated
with differentiation grade, advanced stage and large neck
lymph node metastases [32]. The comparison of these
data with this present study has to be conducted with
care. Since transcription factors are considered to be active
only in the cell nuclei [33], cytoplasmic staining was not
included into our evaluation. In the present study, TWIST
expression alone didn’t associate with survival. There is
some evidence of positive staining of TWIST and poor
survival in HNSCC and for example in oesophageal SCC
[20,16]. In addition, TWIST expression in the epithelial
compartment of breast carcinoma was associated with
poor survival [34]. Similarly to the situation in breast car-
cinoma, nuclear staining of TWIST in epithelial cancer
cells was uncommon with two thirds of tumors lacking
immunoreactivity [34]. A similar observation was seen
also in the recent study of HNSCC [20]. In oesophageal
SCC and cervical SCC, TWIST immunoreactivity was
more abundant [16,17]. Evidently, tumors of different sites
and histology vary in their expression of TWIST. There is
also variation between classifying strategies in different
publications such as diverge cut points between positive
and negative values and in some studies also staining
intensity has been evaluated.
In the present study, patients with epithelial cell nuclei
expression of TWIST tended to have more neck lymph
node metastases. In breast tumor cell lines, TWIST has
been shown to promote early steps of tumor metastasis,
where tumor cells gain access to circulation [14]. TWIST
expression also correlates with distant metastases for
example in esophageal SCC [35]. However, the metastatic
event is a complex process with many phases and there
are several other factors which regulate it.
T h e r ea r en op u b l i s h e dd a t aa b o u tt h eh a l f - l i f eo f
TWIST or on its stability in cell nucleus but SNAI1 has
shown to be highly unstable [33]. As is typical for tran-
scription factors it is probable that TWIST is expressed in
tumor cells for only a very short time which might explain
Table 4 Expression of TWIST and/or SNAI1 in tumor stroma in different sites
Stromal expression of TWIST and/or SNAI1
Site EMT-n (%) TWIST or SNAI1 + n (%) EMT+n (%) p
Oropharynx 33 (30) 22 (20) 14 (13) 0.023
Hypopharynx 9 (8) 16 (15) 15 (14)
Figure 2 Kaplan-Meier univariate 5-year survival analysis in pharyngeal squamous cell carcinoma. In the EMT- group both TWIST and
SNAI1 were negative and in EMT+ group both transcription factors were positive. In group others, both or either TWIST or SNAI1 were
expressed in tumor stroma. Absence of TWIST and SNAI1 expression in tumor stroma predicted better DSS and OS A). Survival was poorer when
one or both transcription factors were positive in tumor stroma B).
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TWIST in their cell nucleus. Some of the stromal cells
may represent transformed epithelial cancer cells under-
going EMT [7]. Tumor cells undergoing EMT lose their
epithelial characteristics, and a proportion of stromal cells
might represent transformed tumor cells. Furthermore, as
a response to growth factors, transcription factors might
stimulate the conversion of stromal fibroblasts into more
motile myofibroblasts [36]. There are also non-neoplastic
activated fibroblastic cells in tumor stroma which may
express transcription factors via the interaction with
epithelial cancer cells. These stromal cells might also
express TWIST or SNAI1 and cannot be distinguished by
immunohistochemistry alone from EMT transformed
stromal cells.
Elevated nuclear transcription factor expression of
TWIST and SNAI1 in tumor stroma may be evidence of
ongoing EMT in pharyngeal squamous cell carcinoma. In
line with this, tumors with negative transcription factor
expression were smaller and had a better prognosis than
tumors with positive expression. Ongoing EMT can thus
be related to tumor progression in pharyngeal squamous
cell carcinoma.
The prognosis of PSCC tended to worsen in conjunction
with the increased stromal expression of these transcrip-
tion factors. Other studies with TWIST and SNAI1 also
support the hypothesis that these two transcription factors
act in collaboration to promote EMT [15,19]. Even though
they are regulated independently [15]. In the present study
only advanced stage and a high Karnofsky performance
status score were independent prognostic factors in the
multivariate analysis. However, co-expression of the tran-
scription factors, a sign of undergoing EMT, tended to
associate with larger tumor size and more advanced stage.
There is evidence of complex communication taking place
between tumor cells and their microenvironment [4]. The
transcription factors involved in EMT promotion are
induced in cancer cells in response to signal released by
activated stroma [9].
Conclusion
In summary, we showed that the TWIST and SNAI1
expression in stromal cells is associated with histopatho-
logical and clinical characteristics that indicate progres-
sive disease. Negative expression of these EMT-
promoting transcription factors predicts a better out-
come. These findings emphasize the importance of the
tumor microenvironment in enhancing cancer growth
and facilitating metastasis.
List of Abbreviations
EMT: epithelial-mesenchymal transition; HNSCC: head and neck squamous
cell carcinoma; DSS: disease specific survival; OS: overall survival; PBS:
phosphate buffered saline; PSCC: pharyngeal squamous cell carcinoma; SCC:
squamous cell carcinoma
Acknowledgements
We kindly thank the late Professor Ismo Virtanen for providing the Snai1-
antibody used in this study.
We thank Helena Kemiläinen and Aija Parkkinen for their skilful technical
assistance.
This study was supported by Finnish Cancer Foundation, The North Savo
Cancer Fund, Special Government Funding (EVO) of Kuopio University
Hospital, Cancer Center of Eastern Finland, the strategic funding of the
University of Eastern Finland and the Finnish Lung Health Association (Filha).
Author details
1Department of Otorhinolaryngology - Head and Neck Surgery, Kuopio
University Hospital, P.O.Box 1777, FI-70211 Kuopio, Finland.
2Institute of
Clinical Medicine, Otorhinolaryngology - Head and Neck Surgery, University
of Eastern Finland, P.O.Box 1627, FI-70211 Kuopio, Finland.
3Institute of
Clinical Medicine, Pathology and Forensic Medicine, University of Eastern
Finland, P.O.Box 1627, FI-70211 Kuopio, Finland.
4Department of Clinical
Pathology, Kuopio University Hospital, P.O.Box 1777, FI-70211 Kuopio,
Finland.
5Biocenter Kuopio and Cancer Center of Eastern Finland, University
of Eastern Finland, P.O.Box 1627, FI-70211 Kuopio, Finland.
Authors’ contributions
AJ-M, HT, YS and RS carried out the IHC analysis. AJ-M, MN-M, MPU, V-MK
and AM participated in study design and statistical analysis. AJ-M and MN-M
drafted the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 March 2011 Accepted: 11 August 2011
Published: 11 August 2011
References
1. Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet
2008, 371(9625):1695-1709.
2. Ragin CC, Modugno F, Gollin SM: The epidemiology and risk factors of
head and neck cancer: a focus on human papillomavirus. J Dent Res
2007, 86(2):104-114.
3. Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J
Med 2001, 345(26):1890-1900.
4. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat
Rev Cancer 2009, 9(4):239-252.
5. Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour
stroma in cancer. Nat Rev Cancer 2004, 4(11):839-849.
6. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7(2):131-142.
7. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal
states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009,
9(4):265-273.
8. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG,
Portillo F, Nieto MA: The transcription factor snail controls epithelial-
mesenchymal transitions by repressing E-cadherin expression. Nat Cell
Biol 2000, 2(2):76-83.
9. Ansieau S, Bastid J, Doreau A, Morel A-P, Bouchet BP, Thomas C, Fauvet F,
Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-
Wittmann S, Caron de Fromentel C, Puisieux A: Induction of EMT by twist
proteins as a collateral effect of tumor-promoting inactivation of
premature senescence. Cancer Cell 2008, 14(1):79-89.
10. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L,
Doglioni C, Beach DH, Hannon GJ: Twist is a potential oncogene that
inhibits apoptosis. Genes Dev 1999, 13(17):2207-2217.
11. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA: Snail
blocks the cell cycle and confers resistance to cell death. Genes Dev
2004, 18(10):1131-1143.
12. Moreno-Bueno G, Portillo F, Cano A: Transcriptional regulation of cell
polarity in EMT and cancer. Oncogene 2008, 27(55):6958-6969.
Jouppila-Mättö et al. BMC Cancer 2011, 11:350
http://www.biomedcentral.com/1471-2407/11/350
Page 7 of 813. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW,
Wu Y, Hicklin DJ, Ellis LM: Vascular endothelial growth factor receptor-1
activation mediates epithelial to mesenchymal transition in human
pancreatic carcinoma cells. Cancer Res 2006, 66(1):46-51.
14. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C,
Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master
regulator of morphogenesis, plays an essential role in tumor metastasis.
Cell 2004, 117(7):927-939.
15. Yang MH, Chen CL, Chau GY, Chiou SH Su CW, Chou TY, Peng WL, Wu JC:
Comprehensive analysis of the independent effect of twist and snail in
promoting metastasis of hepatocellular carcinoma. Hepatology 2009,
50(5):1464-1474.
16. Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T,
Uchikado Y. Kita Y, Tamotsu K, Sakamoto A, Owaki T, Aikou T: Significance
of Twist expression and its association with E-cadherin in esophageal
squamous cell carcinoma. J Exp Clin Cancer Res 2009, 28:158.
17. Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, Nomura S,
Kikkawa F: Twist expression in patients with cervical cancer is associated
with poor disease outcome. Ann Oncol 2008, 19(1):81-85.
18. Jouppila-Mättö A, Tuhkanen H, Soini Y, Pukkila M, Närkiö-Mäkelä M,
Sironen R, Virtanen I, Mannermaa A, Kosma V-M: Transcription factor Snai1
expression and poor survival in pharyngeal squamous cell carcinoma.
Histol Histopathol 2011, 26(4):443-449.
19. Schwock J, Bradley G, Ho JC, Perez-Ordonez B, Hedley DW, Irish JC,
Geddie WR: SNAI1 expression and the mesenchymal phenotype: an
immunohistochemical study performed on 46 cases of oral squamous
cell carcinoma. BMC Clin pathol 2010, 10:1.
20. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC Wu KJ:
Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell
Biol 2008, 10(3):295-305.
21. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ: Prognostic significance
of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in
resectable non-small cell lung cancer. Thorax 2009, 64(12):1082-1089.
22. Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, Pirinen RT, Johansson RT,
Valtonen HJ, Juhola MT, Kosma VM: Nuclear beta catenin expression is
related to unfavourable outcome in oropharyngeal and hypopharyngeal
squamous cell carcinoma. J Clin Pathol 2001, 54(1):42-47.
23. Histological typing of tumours of the upper respiratory tract and ear.
Edited by: Shanmugaratnam K, Sobin LH. Heidelberg: Springer-Verlag; , 2
1991:.
24. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors. In Union
Internationale Contre le Cancer and the American Joint Committee on Cancer
Edited by: Sobin LH, Fleming ID , Fifth 1997, 80(9):1803-1804.
25. Karnofsky D, Abelmann W, Craver L, Burchenal J: The use of nitrogen
mustards in the palliative treatment of carcinoma. 1948, 1:634-635-656.
26. Franci C, Takkunen M, Dave N, Alameda F, Gómez S, Rodríguez R, Escrivà M,
Montserrat-Sentís B, Baró T, Garrido M, Bonilla F, Virtanen I, García de
Herreros A: Expression of Snail protein in tumor-stroma interface.
Oncogene 2006, 25(37):5134-5144.
27. Takkunen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A,
Virtanen I: Snail-dependent and -independent epithelial-mesenchymal
transition in oral squamous carcinoma cells. J Histochem Cytochem 2006,
54(11):1263-1275.
28. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F,
Bittard H, Wallerand H: The expression of Twist has an impact on survival
in human bladder cancer and is influenced by the smoking status. Urol
Oncol 2009, 27(3):268-276.
29. Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H, Takenaka T,
Yohena T, Maehara Y: Induction of epithelial-mesenchymal transition-
related genes by benzo[a]pyrene in lung cancer cells. Cancer 2007,
110(2):369-374.
30. Yang MH, Hsu DS-S, Wang H-W Wang HJ, Lan HY, Yang WH, Huang CH,
Kao SY, Tzeng CH Tai SK, Chang SY, Lee OKS Wu KJ: Bmi1 is essential in
Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010,
12(10):982-92.
31. Horikawa T, Yoshizaki T, Kondo S, Furukawa M, Kaizaki Y, Pagano JS:
Epstein-Barr Virus latent membrane protein 1 induces Snail and
epithelial-mesenchymal transition in metastatic nasopharyngeal
carcinoma. Br J Cancer 2011, 104(7):1160-7.
32. Ou DL, Chien HF, Chen CL, Lin TC, Lin LI: Role of Twist in head and neck
carcinoma with lymph node metastasis. Anticancer Res 2008,
28(2B):1355-1359.
33. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual regulation
of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-
mesenchymal transition. Nat Cell Biol 2004, 6(10):931-940.
34. Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P,
Mannermaa A, Kosma VM: Transcription factors zeb1, twist and snai1 in
breast carcinoma. BMC Cancer 2011, 16;11(2):73.
35. Yuen HF, Chan YP, Wong MLY, Kwok WK, Chan KK, Lee PY, Srivastava G,
Law SYK, Wong YC, Wang X, Chan KW: Upregulation of Twist in
oesophageal squamous cell carcinoma is associated with neoplastic
transformation and distant metastasis. J Clin Pathol 2007, 60(5):510-514.
36. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006,
6(5):392-401.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/350/prepub
doi:10.1186/1471-2407-11-350
Cite this article as: Jouppila-Mättö et al.: Twist and snai1 expression in
pharyngeal squamous cell carcinoma stroma is related to cancer
progression. BMC Cancer 2011 11:350.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jouppila-Mättö et al. BMC Cancer 2011, 11:350
http://www.biomedcentral.com/1471-2407/11/350
Page 8 of 8